| Citation: | Xuelian Fu, Jing Zhao, Han Meng, Mengting Wang, Hong Qiao. Protective mechanism of Ramulus Mori (Sangzhi) Alkaloids on T2DM combined with MASLD by hepatic lipid metabolism and gut microbiota analyses[J]. Frigid Zone Medicine, 2025, 5(4): 242-251. doi: 10.1515/fzm-2025-0026 |
| [1] |
Ferguson D, Finck B N. Emerging therapeutic approaches for the treatment of MASLD and type 2 diabetes mellitus. Nat Rev Endocrinol, 2021; 17(8): 484-495. doi: 10.1038/s41574-021-00507-z
|
| [2] |
Targher G, Corey K E, Byrne C D, et al. The complex link between MASLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol, 2021; 18(9): 599-612. doi: 10.1038/s41575-021-00448-y
|
| [3] |
Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol, 2022; 10(4): 284-296. doi: 10.1016/S2213-8587(22)00003-1
|
| [4] |
En Li Cho E, Ang C Z, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: An updated systematic review and meta-analysis. Gut, 2023; 72(11): 2138-2148. doi: 10.1136/gutjnl-2023-330110
|
| [5] |
Tanase D M, Gosav E M, Costea C F, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (MASLD). J Diabetes Res, 2020; 2020: 3920196. doi: 10.1155/2020/3920196
|
| [6] |
Poustchi H, Alaei-Shahmiri F, Aghili R, et al. Hepatic steatosis and fibrosis in type 2 diabetes: A risk-based approach to targeted screening. Arch Iran Med, 2021; 24(3): 177-186. doi: 10.34172/aim.2021.28
|
| [7] |
Hong S H, Choi K M. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci, 2020; 21(2): 494. doi: 10.3390/ijms21020494
|
| [8] |
Zhou M, Liu X, Wu Y, et al. Liver lipidomics analysis revealed the protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease. J Ethnopharmacology, 2024; 329: 118160. doi: 10.1016/j.jep.2024.118160
|
| [9] |
Alfadda A A, Almaghamsi A M, Sherbeeni S M, et al. Alterations in circulating lipidomic profile in patients with type 2 diabetes with or without non-alcoholic fatty liver disease. Front Mol Biosci, 2023; 10: 1030661. doi: 10.3389/fmolb.2023.1030661
|
| [10] |
Schoeler M, Ellero-Simatos S, Birkner T, et al. The interplay between dietary fatty acids and gut microbiota influences host metabolism and hepatic steatosis. Nat Commun, 2023; 14(1): 5329. doi: 10.1038/s41467-023-41074-3
|
| [11] |
An X, Yang X, Ding X, et al. Ramulus Mori (Sangzhi) alkaloids tablets for diabetes mellitus: A regulatory perspective. Fitoterapia, 2023; 166: 105444. doi: 10.1016/j.fitote.2023.105444
|
| [12] |
Sun Q W, Lian C F, Chen Y M, et al. Ramulus Mori (Sangzhi) alkaloids ameliorate obesity-linked adipose tissue metabolism and inflammation in mice. Nutrients, 2022; 14(23): 5050. doi: 10.3390/nu14235050
|
| [13] |
Yang Y, Wu L, Lv Y, et al. LC-MS/MS based untargeted lipidomics uncovers lipid signatures of late-onset preeclampsia. Biochimie, 2023; 208: 46-55. doi: 10.1016/j.biochi.2022.12.002
|
| [14] |
Bailey L S, Huang F, Gao T, et al. Characterization of glycosphingolipids and their diverse lipid forms through two-stage matching of LC-MS/MS Spectra. Anal Chem, 2021; 93(6): 3154-3162. doi: 10.1021/acs.analchem.0c04542
|
| [15] |
Liu D, Ye J, Yan Y, et al. Ramulus Mori (Sangzhi) alkaloids regulates gut microbiota disorder and its metabolism profiles in obese mice induced by a high-fat diet. Front Pharmacol, 2023; 14: 1166635. doi: 10.3389/fphar.2023.1166635
|
| [16] |
Liu W, Xu S, Zhang B, et al. Ramulus Mori (Sangzhi) alkaloids alleviate diabetic nephropathy through improving gut microbiota disorder. Nutrients, 2024; 16(14): 2346. doi: 10.3390/nu16142346
|
| [17] |
Wang F, Xu S J, Ye F, et al. Integration of transcriptomics and lipidomics profiling to reveal the therapeutic mechanism underlying Ramulus Mori (Sangzhi) Alkaloids for the treatment of liver lipid metabolic disturbance in high-fat-diet/streptozotocin-induced Diabetic Mice. Nutrients, 2023; 15(18): 3914. doi: 10.3390/nu15183914
|